Ogilvy lands Endo pain, men's health work

Share this article:
Ogilvy lands Endo pain, men's health work
Ogilvy lands Endo pain, men's health work

Endo Health Solutions has named Ogilvy Public Relations (Ogilvy PR) as agency partner for its pharmaceutical business. Oglivy PR will offer communications support to the company's men's health and pain-management businesses.

PRWeek reported that the selection process took place over a few weeks and that it is an annual deal.

“Ogilvy's healthcare expertise combined with its global network and resource make this the right partnership as Endo broadens its reach in branded pharmaceuticals,” stated Blaine Davis, Endo SVP, corporate affairs, in a press release.

Endo Pharmaceuticals owns two testosterone injections, Delatestyrl and Fortesta, in addition to a number of pain management products, including Opana ER as well as Percocet, Percodan, Voltaren and Zydone.

Other brands include Fortesta Gel for Low-T, Supprelin LA for central precocious puberty, and bladder cancer treatment Valstar.

The FDA decided last spring to allow generic competition for Opana ER. Endo's 2013 third-quarter earnings presentation notes that commercial support for the brand is continuing, with a focus on driving organic growth through specialty promotion. Endo Health bought Canadian drugmaker Paladin Labs last November, netting the firm pain drug Zohydro, a non-combination hydrocodone product.

FDA approved Zohydro in late October, only one day after federal regulators announced that it would aim to tighten the control of hydrocodone products, like Vicodin, in an effort to reduce misuse and abuse of these products, by moving them from Schedule III to Schedule II.

Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.